The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A
2a
adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I).